Tan Owen, Schofield Deborah J, Shrestha Rupendra
1GenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, Australia.
J Natl Compr Canc Netw. 2021 Aug 6;20(2):126-135. doi: 10.6004/jnccn.2020.7802.
This study used a linked dataset consisting of all childhood cancers recorded over the course of 10 years in New South Wales (NSW), Australia, to evaluate the hospital and emergency department costs (from a payer perspective) and resources used by patients with childhood cancer. We also analyzed determinants responsible for high-frequency hospital admissions, hospital length of stay (LoS), and hospital costs.
We analyzed linked data at the individual patient level for a retrospective cohort of 2,966 patients with cancer aged <18 years with a diagnosis date between 2001 and 2012 from the NSW Central Cancer Registry, Australia. We reported costs and use of hospitalization and emergency department presentation 1 year before the date of diagnosis, 1 year after diagnosis, and 2 to 5 years after diagnosis. We also examined the association between cancer types and hospital admission and hospital costs from the payer perspective. Patient characteristics associated with the frequency of hospital admissions, hospital LoS, and hospital costs were also determined using a generalized linear model.
Most hospital admission costs occurred in the first year after diagnosis, accounting for >70% of hospital costs within 5 years after diagnosis. The estimated median annual cost of hospitalization in the first year after diagnosis was A$88,964 (interquartile range [IQR], A$34,399-A$163,968) for patients diagnosed at age 0 to 14 years and A$23,384 (IQR, A$5,585-A$91,565) for those diagnosed at age 15 to 17 years. Higher frequency of hospital admissions, hospital LoS, and hospital costs were significantly associated with younger age at cancer diagnosis, cancer metastases, and living in remote/disadvantaged socioeconomic areas.
Our study represents one of the first in Australia to include detailed hospitalization cost information for all childhood cancer cases. This study highlights the high hospital use by pediatric patients and the importance of early diagnosis. Our findings also demonstrate the health inequities experienced by patients from remote areas and the lowest socioeconomic areas.
本研究使用了一个关联数据集,该数据集包含澳大利亚新南威尔士州(NSW)10年间记录的所有儿童癌症病例,以评估儿童癌症患者的医院和急诊科费用(从支付方角度)以及所使用的资源。我们还分析了导致高频住院、住院时长(LoS)和医院费用的决定因素。
我们对来自澳大利亚新南威尔士州中央癌症登记处的2966例年龄小于18岁、诊断日期在2001年至2012年之间的癌症患者的回顾性队列进行了个体患者层面的关联数据分析。我们报告了诊断日期前1年、诊断后1年以及诊断后2至5年的住院费用和急诊科就诊情况及使用情况。我们还从支付方角度研究了癌症类型与住院和医院费用之间的关联。使用广义线性模型确定了与住院频率、住院LoS和医院费用相关的患者特征。
大多数住院费用发生在诊断后的第一年,占诊断后5年内医院费用的70%以上。0至14岁诊断的患者,诊断后第一年的估计住院费用中位数为88,964澳元(四分位间距[IQR],34,399澳元至163,968澳元),15至17岁诊断的患者为23,384澳元(IQR,5,585澳元至91,565澳元)。癌症诊断时年龄较小、癌症转移以及居住在偏远/社会经济条件不利地区与更高的住院频率、住院LoS和医院费用显著相关。
我们的研究是澳大利亚首批纳入所有儿童癌症病例详细住院费用信息的研究之一。本研究突出了儿科患者的高住院使用率以及早期诊断的重要性。我们的研究结果还表明了偏远地区和社会经济地位最低地区患者所经历的健康不平等。